Amneal Pharmaceuticals Company (I) Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Amneal Pharmaceuticals Company (I) Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $1.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Amneal Pharmaceuticals Company (I) Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $1.1M Trade | TransData Nexus

Amneal Pharmaceuticals Company (I) Private Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $1.1M Total Trade · DGFT Verified

Amneal Pharmaceuticals Company (I) Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.1M across 3 products in 3 therapeutic categories. Based on 21 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Propranolol ($550.0K), Methylprednisolone ($300.0K), Fulvestrant ($200.0K).

Amneal Pharmaceuticals Company (I) Private Limited — Export Portfolio & Destination Treemap

Amneal Pharmaceuticals Company (I) Private Limited pharmaceutical export portfolio — 3 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Amneal Pharmaceuticals Company (I) Private Limited? — Company Overview & Market Position

Amneal Pharmaceuticals Company (I) Private Limited, incorporated on April 7, 2006, is a private pharmaceutical manufacturer based in Ahmedabad, Gujarat, India. The company's Corporate Identification Number (CIN) is U24231GJ2006PTC048109. As of the latest available data, Amneal Pharmaceuticals Private Limited has an authorized capital of ₹330 million and a paid-up capital of ₹308 million. The company is primarily engaged in the manufacturing of pharmaceutical products, including finished formulations such as tablets, capsules, syrups, and injections.

Amneal Pharmaceuticals Company (I) Private Limited is a subsidiary of Amneal Pharmaceuticals, Inc., a global biopharmaceutical company headquartered in Bridgewater, New Jersey, USA. Amneal Pharmaceuticals, Inc. was founded in 2002 by brothers Chirag and Chintu Patel, who were inspired by their father, Kanu Patel, an industrial pharmacist and pharmaceutical regulatory inspector in India. The company has grown to become one of the largest manufacturers of generic drugs in the United States, with a diverse portfolio of over 290 generic and specialty pharmaceuticals.

What Does Amneal Pharmaceuticals Company (I) Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Propranolol$550.0K

Product Portfolio — Top 3 by Export Value

Amneal Pharmaceuticals Company (I) Private Limited exports 3 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Propranolol	Cardiovascular	$550.0K	11	0.9%	5
2	Methylprednisolone	Corticosteroids	$300.0K	6	1.0%	9
3	Fulvestrant	Advanced Oncology	$200.0K	4	1.4%	8

Amneal Pharmaceuticals Company (I) Private Limited exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $1.1M. The top category is Cardiovascular (52.4% of portfolio), followed by Corticosteroids (28.6%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Amneal Pharmaceuticals Company (I) Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Amneal Pharmaceuticals Company (I) Private Limited operates manufacturing facilities in Ahmedabad, Gujarat, India. The company's registered office is located at 901-911, Iscon Elegance, Opp. Karnavati Club, S.G. Highway, Ahmedabad, Gujarat, 380015. While specific details regarding the capacities and specializations of these facilities are not publicly disclosed, Amneal Pharmaceuticals, Inc. has made significant investments in India, including the construction of a 293,000 square-foot manufacturing facility near Ahmedabad in 2021 to produce injectable medicines.

3Key Leadership

As of the latest available information, Amneal Pharmaceuticals Company (I) Private Limited is led by key executives from its parent company, Amneal Pharmaceuticals, Inc. Chirag Patel serves as the Co-Chief Executive Officer (CEO) and Co-Founder of Amneal Pharmaceuticals, Inc. Chintu Patel, also a Co-Founder, holds the position of Co-CEO. Both brothers have been instrumental in the company's growth and strategic direction. Specific details regarding the Chief Financial Officer (CFO) and other key executives of the Indian subsidiary are not publicly disclosed.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Amneal Pharmaceuticals Company (I) Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Amneal Pharmaceuticals Company (I) Private Limited, as a subsidiary of Amneal Pharmaceuticals, Inc., operates in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The parent company has a history of obtaining regulatory approvals for its products in these regions. For instance, in September 2023, Amneal received approval from the U.S. Food and Drug Administration (FDA) for calcium gluconate in sodium chloride injection, a product currently on the FDA's shortage list. Additionally, in December 2025, Amneal received FDA approval for albuterol sulfate inhalation aerosol, a generic equivalent of PROAIR® HFA. These approvals demonstrate Amneal's commitment to meeting regulatory standards in key markets.

2Emerging Markets

Amneal Pharmaceuticals Company (I) Private Limited has made strategic investments to penetrate emerging markets, particularly in India. The company began selling medication in India in October 2022, marking its entry into the Indian pharmaceutical market. In September 2023, Amneal received approval to launch its first product in China, Sevelamer carbonate, and has six other products under review. These initiatives reflect Amneal's efforts to expand its presence in emerging markets and enhance access to essential medicines.

Geographic Strategy

Amneal Pharmaceuticals Company (I) Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Amneal Pharmaceuticals, Inc., the parent company of Amneal Pharmaceuticals Company (I) Private Limited, has a robust history with the U.S. Food and Drug Administration (FDA). In September 2023, Amneal received FDA approval for calcium gluconate in sodium chloride injection, a product on the FDA's shortage list. Additionally, in December 2025, the company received FDA approval for albuterol sulfate inhalation aerosol, a generic equivalent of PROAIR® HFA. These approvals underscore Amneal's commitment to meeting FDA standards and addressing critical shortages in the U.S. market.

2WHO & EU GMP

Specific details regarding Amneal Pharmaceuticals Company (I) Private Limited's compliance with World Health Organization (WHO) prequalification and European Union Good Manufacturing Practice (EU GMP) certifications are not publicly disclosed. However, Amneal Pharmaceuticals, Inc. has a history of obtaining regulatory approvals in various markets, indicating adherence to international manufacturing standards. For example, in December 2025, Amneal received FDA approval for albuterol sulfate inhalation aerosol, a generic equivalent of PROAIR® HFA.

3CDSCO & Indian Regulatory

Amneal Pharmaceuticals Company (I) Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Amneal Pharmaceuticals Company (I) Private Limited operates in a competitive landscape, particularly in the generic pharmaceutical sector. The company's parent, Amneal Pharmaceuticals, Inc., competes with other major generic drug manufacturers in the U.S. market. For instance, in December 2025, Amneal received FDA approval for albuterol sulfate inhalation aerosol, a generic equivalent of PROAIR® HFA, indicating active competition in the respiratory therapeutic segment. Additionally, the company's expansion into emerging markets like India and China introduces competition from both local and international pharmaceutical companies.

2Key Differentiators

Amneal Pharmaceuticals Company (I) Private Limited differentiates itself through its affiliation with Amneal Pharmaceuticals, Inc., a global biopharmaceutical company with a diverse portfolio of over 290 generic and specialty pharmaceuticals. The company's strategic focus on complex dosage forms, including biosimilars and injectables, positions it to address unmet medical needs and enhance patient access to essential medicines. For example, in December 2025, Amneal received FDA approval for albuterol sulfate inhalation aerosol, a generic equivalent of PROAIR® HFA, demonstrating its capability in complex respiratory drug delivery.

Strategic Position

Buyer Due Diligence Brief — Evaluating Amneal Pharmaceuticals Company (I) Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Amneal Pharmaceuticals Company (I) Private Limited has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products. The company's total export value from 2022 to 2026 is $1.1 million USD, with 21 shipments across three therapeutic categories. The top three exported products are Propranolol ($550K, Rank #5, 0.9% market share), Methylprednisolone ($300K, Rank #9, 1.0% market share), and Fulvestrant ($200K, Rank #8, 1.4% market share). The portfolio concentration is high, with the top five products accounting for 100% of

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Amneal Pharmaceuticals Company (I) Private Limited

How many pharmaceutical products does Amneal Pharmaceuticals Company (I) Private Limited export from India?

Amneal Pharmaceuticals Company (I) Private Limited exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Propranolol ($550.0K), Methylprednisolone ($300.0K), Fulvestrant ($200.0K). Total export value is $1.1M.

What is Amneal Pharmaceuticals Company (I) Private Limited's total pharmaceutical export value?

Amneal Pharmaceuticals Company (I) Private Limited's total pharmaceutical export value is $1.1M, based on 21 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Amneal Pharmaceuticals Company (I) Private Limited cover?

Amneal Pharmaceuticals Company (I) Private Limited exports across 3 therapeutic categories. The largest are Cardiovascular (52.4%, 1 products), Corticosteroids (28.6%, 1 products), Advanced Oncology (19.0%, 1 products).

Get Full Amneal Pharmaceuticals Company (I) Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.